𝔖 Bobbio Scriptorium
✦   LIBER   ✦

435 PUBLICATION Comparison of epirubicin and vinorelbine with cyclophosphamide, epirubicin, and fluorouracil as neoadjuvant chemotherapy for operable breast cancer

Book ID
118623015
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
140 KB
Volume
3
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I trial of adjuvant chemotherapy w
Phase I trial of adjuvant chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil (CEF) for stage II breast cancer
✍ Stephen E. Jones; Robert G. Mennel; George N. Peters; Mary Alice Westrick; Barry πŸ“‚ Article πŸ“… 1988 πŸ› Springer US 🌐 English βš– 263 KB

Epirubicin is a new anthracycline with a potentially more favorable toxicity profile than the parent compound, doxorubicin. Accordingly, the feasibility and toxicity of 6 courses of adjuvant chemotherapy with cyclophosphamide (C), epirubicin (E), and 5-fluorouracil (F) were assessed in 10 patients w

Randomized trial comparing cyclophospham
Randomized trial comparing cyclophosphamide, methotrexate, and 5–fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma
✍ Giorgio Cocconi; Beatrice Di Blasio; Corrado Boni; Giancarlo Bisagni; Guido Ceci πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 84 KB

## Abstract ## BACKGROUND According to the overview of Early Breast Cancer Trialists' Collaborative Group, anthracycline containing regimens are superior to cyclophosphamide, methotrexate, and 5–fluorouracil (CMF) as adjuvant chemotherapy for breast carcinoma, but no comparative information is ava